(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
4 days till quarter result
(tns 2024-05-08)
Expected move: +/- 9.54%
Live Chart Being Loaded With Signals
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States...
Stats | |
---|---|
今日成交量 | 4.04M |
平均成交量 | 2.24M |
市值 | 2.95M |
EPS | $0 ( 2024-03-20 ) |
下一个收益日期 | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0528 |
ATR14 | $0.0130 (32.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-04-10 | Petrini Maria Carolina | Buy | 400 000 | Nonqualified Stock Option (Right to Buy) |
2023-04-10 | Petrini Maria Carolina | Buy | 0 | |
2023-02-01 | Mcintyre Gail Frances | Buy | 700 000 | Stock Option (Right to Buy) |
2023-02-01 | Geller Robert B. | Buy | 400 000 | Stock Option (Right to Buy) |
2023-02-01 | Howard Rudy | Buy | 400 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 72 486 477 | Sell: 119 333 |
音量 相关性
Aravive Inc 相关性 - 货币/商品
Aravive Inc 财务报表
Annual | 2022 |
营收: | $9.14M |
毛利润: | $-57.80M (-632.60 %) |
EPS: | $-2.22 |
FY | 2022 |
营收: | $9.14M |
毛利润: | $-57.80M (-632.60 %) |
EPS: | $-2.22 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.48 |
FY | 2020 |
营收: | $5.69M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.930 |
Financial Reports:
No articles found.
Aravive Inc
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。